Novo Nordisk Announces U.S. Launch of NovoFine® Plus, a New Pen Needle for Patients with Diabetes

NovoFine® Plus is the shortest and thinnest pen needle in the Novo Nordisk family of needles designed for diabetes pens

News provided by

Oct 29, 2014, 08:07 ET

PLAINSBORO, N.J., Oct. 29, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its shortest and thinnest pen needle, NovoFine^® Plus, in the United States. NovoFine^® Plus is a universal needle that works with all currently available insulin and some GLP-1 receptor agonist pens. The Food and Drug Administration (FDA) cleared the 510(k) application for NovoFine^® Plus earlier this year.

NovoFine^® Plus, which measures 32 gauge and 4 mm long, is one of the shortest, thinnest diabetes pen needles available today. Thinner needles are designed for less pain when injecting.^[1]The new needle uses SuperFlow^TM Technology, which is designed to enhance flow rate and reduce the dosage force when making the injection. The needle is also designed to resist bending or breaking.

"Novo Nordisk launched the world's first pen needle in 1985, and since then has strived to improve the injection experience for patients by developing smaller and thinner needles," said Camille Lee, senior vice president, diabetes marketing. "At the width of two human hairs, NovoFine^® Plus is now our thinnest needle, and it features many improvements that are designed to cause less pain upon injection."

Pen needles are an integral part of the treatment experience for patients who rely on injectable therapies. Novo Nordisk is currently the only company that offers all components of the delivery system, with integrated development of insulin, needles, and pens. NovoFine^® Plus joins an entire family of Novo Nordisk pen needles, including NovoTwist^® 32G Tip, NovoFine^® 32G Tip and NovoFine^® Autocover^® 30G.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk-us.com or follow our news in the U.S. on Twitter: @NovoNordiskUS.

About Diabetes
In the United States, 29.1 million people have diabetes,^[2]a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life.

NovoFine^®Plus, NovoTwist^®, NovoFine^®, and NovoFine^® Autocover^® are registered trademarks of Novo Nordisk A/S.

^{^[1]} Arendt-Nielsen L, et al. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1/2):37-43.
^{^[2]} National Diabetes Statistics Report, 2014. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/diabetes/pubs/statsreport14.htm. Accessed September 12, 2014.

PDF - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/novo-finefact-sheet.pdf

SOURCE Novo Nordisk